Dementia is increasingly prevalent with age and negatively affects the quality of life of both patients and families.
1 Unfortunately, the pathological changes responsible for dementia appear to be irreversible by the time of diagnosis. Treatments are few, very limited in efficacy, and target symptoms.
2 Therefore, identifying modifiable biomarkers that may estimate the risk for subsequent cognitive decline is critical. Such measurable biomarkers could identify high-risk patients appropriate for further testing of potential disease-modifying therapies.